Semaglutide and Tirzepatide Match Surgery Results Short-Term in Massive Obesity Treatment Comparison | Research

The takeaway

In the largest network meta-analysis of obesity treatments, semaglutide and tirzepatide showed non-inferior short-term weight loss compared to bariatric surgery, though surgery remained superior long-term.

>10% weight loss
Both tirzepatide and most bariatric surgeries achieved >10% total body weight loss at 6-12 months

What the researchers found

At 26-52 weeks, tirzepatide achieved >10% TBWL comparable to most surgeries. Long-term, surgical procedures (RYGB, SG, SADI, BPD) remained superior. Semaglutide and tirzepatide showed no inferior short-term results vs MBS.

Why it matters

This is the most comprehensive comparison of all obesity treatments to date, directly informing clinical decisions about when to recommend medications versus procedures for different patients.

How the study worked

GRADE-based network meta-analysis of 139 RCTs (54 MBS, 21 EBP, 64 OMM) analyzing total body weight loss percentage at four timepoints up to 3+ years, registered in PROSPERO.

What this study cannot tell us

Long-term data lacking for most medications and all endoscopic procedures. Indirect comparisons through network meta-analysis have inherent limitations. Studies varied in patient populations and follow-up methods.

How to read the evidence

GRADE-based network meta-analysis of 139 RCTs—the highest level of evidence synthesis. Limitations are inherent to indirect comparisons and variable follow-up lengths.

When this study was published

Published in 2025 with studies through December 2024, capturing the latest trial data for all major obesity treatments.

The bigger picture

The obesity treatment landscape is rapidly evolving. This analysis shows that GLP-1-based peptide drugs have closed the gap with surgery for short-term weight loss, potentially shifting treatment paradigms toward earlier medication use.

Questions still open

Will tirzepatide and semaglutide maintain their weight loss effects beyond 2-3 years?
Should GLP-1 drugs be tried before surgery, or are some patients better served by immediate surgical intervention?
How do the cost-effectiveness profiles compare across all these treatment options?

Common questions

Are GLP-1 drugs as effective as weight loss surgery?

In the short term (6-12 months), tirzepatide and semaglutide show comparable weight loss to many surgical procedures. However, long-term data favor surgery, particularly gastric bypass and sleeve gastrectomy, for sustained weight loss.

Which obesity treatment has the fewest side effects?

Medications generally have lower rates of serious adverse events compared to surgery and endoscopic procedures. However, each treatment has its own risk profile, and the best choice depends on individual patient factors.

Read the original research

Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.

Obesity (Silver Spring, Md.), 34(2), 279-293

View on PubMed ↗Publisher’s paper ↗

Citation

De Luca, Maurizio; Cohen, Ricardo V; Belluzzi, Amanda; Navarra, Giuseppe; Di Lorenzo, Nicola; Petry, Tarissa B Z; Sbraccia, Paolo; Busetto, Luca; Buscemi, Silvio; Barazzoni, Rocco; Ragghianti, Benedetta; Mannucci, Edoardo; Monami, Matteo. (2026). Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.. Obesity (Silver Spring, Md.), 34(2), 279-293. https://doi.org/10.1002/oby.70083